Article · Wikipedia archive · Last revised Jul 4, 2026

IPALT

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family. It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT). The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor. It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake. The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001). The chemical synthesis of iPALT has been described. Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002). 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use. iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.

Last revised
Jul 4, 2026
Read time
≈ 1 min
Length
308 w
Citations
12
Source
Wikipedia ↗
iPALT
Clinical data
Other namesALiPT; ASR-3003; ASR3003; N-Isopropyl-N-allyltryptamine; N-Allyl-N-isopropyltryptamine
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-2-amine
PubChem CID
Chemical and physical data
FormulaC16H22N2
Molar mass242.366 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=CC=CC=C21)CC=C
  • InChI=1S/C16H22N2/c1-4-10-18(13(2)3)11-9-14-12-17-16-8-6-5-7-15(14)16/h4-8,12-13,17H,1,9-11H2,2-3H3
  • Key:DYIILRIYTXJTNJ-UHFFFAOYSA-N

iPALT, or ALiPT, also known as N-isopropyl-N-allyltryptamine or by its developmental code name ASR-3003, is a serotonin receptor modulator of the tryptamine family.1 It is an asymmetrical analogue of diisopropyltryptamine (DiPT) and diallyltryptamine (DALT).1 The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.1 It is also a serotonin reuptake inhibitor, but does not inhibit dopamine or norepinephrine reuptake.1 The drug shows rather low potency for many of these actions, with for example 47-fold lower potency as a serotonin 5-HT2A receptor agonist than the known psychedelic drug 5-MeO-iPALT (ASR-3001).1 The chemical synthesis of iPALT has been described.1 Derivatives of iPALT include 5-MeO-iPALT (ASR-3001), 4-HO-iPALT, and 2-Me-iPALT (ASR-3002).1 5-MeO-iPALT is known to be a psychedelic drug in humans and is under development for potential medical use.2345 iPALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.1

See also

See also

References

References

  1. US 20240277665A1, Daley PF, Cozzi NV, Callaway WB, "Asymmetric allyl tryptamines", issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc. 
  2. "Delving into the Latest Updates on Tryptamine(ASRI) with Synapse". Synapse. 16 April 2025. Retrieved 19 April 2025.
  3. Goldstein L (10 July 2023). "Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research". Benzinga. Retrieved 19 April 2025.
  4. Busby M (2 November 2023). "The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown". DoubleBlind Mag. Retrieved 19 April 2025.
  5. Busby M (30 March 2025). "What Happens When You Inherit 500 Psychedelic Compounds?". DoubleBlind Mag. Retrieved 19 April 2025.
External links